Claudia Mendoza-Pinto, Pamela Munguía-Realpozo, Ivet Etchegaray-Morales, Miguel Ángel Saavedra-Salinas, Paulina Cortés-Hernández, Jorge Ayón-Aguilar, Edith Ramírez-Lara, Socorro Méndez Martínez, Mario García-Carrasco
{"title":"Mortality Trends in Polymyositis and Dermatomyositis in Mexico: A General Population-Based Study From 2000 to 2019.","authors":"Claudia Mendoza-Pinto, Pamela Munguía-Realpozo, Ivet Etchegaray-Morales, Miguel Ángel Saavedra-Salinas, Paulina Cortés-Hernández, Jorge Ayón-Aguilar, Edith Ramírez-Lara, Socorro Méndez Martínez, Mario García-Carrasco","doi":"10.1097/RHU.0000000000002211","DOIUrl":"https://doi.org/10.1097/RHU.0000000000002211","url":null,"abstract":"<p><strong>Introduction: </strong>Patients with polymyositis and dermatomyositis (PM/DM) are prone to multiple complications that may lead to increased mortality rates. Data about PM/DM mortality in Mexico are lacking.</p><p><strong>Objective: </strong>The aim of this study was to assess mortality trends in PM/DM in Mexico across 2 decades (2000-2019), overall, by sex, age group, and geographic region.</p><p><strong>Methods: </strong>From 2000 to 2019, PM/DM deaths were identified in Mexican open-access health databases using the International Classification of Diseases, 10th Revision. Age-standardized mortality rates (ASMRs) per 100,000 inhabitants were calculated for PM/DM and non-PM/DM deaths by sex and geographic region. The annual percent change (APC) in ASMR was calculated using Joinpoint Regression Software.</p><p><strong>Results: </strong>We found 11.3 million non-PM/DM deaths and 1456 PM/DM deaths in Mexico during the period 2000-2019. Seventy percent of PM/DM deaths occurred in females. PM/DM ASMR was 0.06-0.07/100,000 inhabitants and higher in females (0.08-0.11/100,000). Remarkably, 40% of PM/DM deaths happened in individuals younger than 45 years. This was almost double the percentage than in non-PM/DM deaths. A significant PM/DM ASMR downtrend was identified from 2007 to 2017 (APC, -3.2%; 95% confidence interval, -5.3 to -1.0; p = 0.008), whereas mortality trends were stable for non-PM/DM deaths. No significant changes through time were identified in PM/DM mortality by geographic region in Mexico; however, an increment in PM/DM to non-PM/DM ASMR ratio was detected in the north (+17.6%) and southeast (+84.9%) of Mexico.</p><p><strong>Conclusions: </strong>Mexico's PM/DM mortality rates have significantly decreased over the past 2 decades, particularly from 2007 to 2017. This trend is more pronounced among younger individuals and those outside the country's southeastern region.</p>","PeriodicalId":14745,"journal":{"name":"JCR: Journal of Clinical Rheumatology","volume":" ","pages":""},"PeriodicalIF":2.4,"publicationDate":"2025-03-12","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"143615043","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":4,"RegionCategory":"医学","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}
{"title":"Noninfectious Uveitis in Pediatric Rheumatology: Long-term Follow-up at Tertiary Centers.","authors":"Nergis Akay, Umit Gul, Oya Koker, Mustafa Asim Erol, Mehmet Yildiz, Elif Kilic Konte, Ebru Altinok, Aybuke Gunalp, Esma Aslan, Fatih Haslak, Amra Adrovic, Sezgin Sahin, Kenan Barut, Didar Ucar, Ilknur Tugal-Tutkun, Ozgur Kasapcopur","doi":"10.1097/RHU.0000000000002220","DOIUrl":"https://doi.org/10.1097/RHU.0000000000002220","url":null,"abstract":"<p><strong>Objectives: </strong>Our study aimed to identify potential predictors for additional systemic involvement in patients with noninfectious uveitis, specifically focusing on their demographic, etiological, clinical, and laboratory data features from the pediatric rheumatology perspective.</p><p><strong>Methods: </strong>Patients with noninfectious uveitis before the age of 18 years and followed up for at least 3 months in 2 tertiary centers of pediatric rheumatology and ophthalmology departments were included in the study. Demographics, etiology, clinical features, laboratory data, and treatments administered were evaluated and compared based on the etiology (idiopathic and systemic disease-related uveitis [SD-U]) and the use of biologic disease-modifying antirheumatic drugs.</p><p><strong>Results: </strong>Of 244 patients (131 with idiopathic uveitis and 113 with SD-U), 141 (57.8%) were female. The median (min-max) age at uveitis diagnosis was 8 (1-17) years, with a median (min-max) follow-up period of 36 (3-216) months. We observed that uveitis was mostly anterior (n = 140, 57.4%), chronic (n = 122, 67.4%), and bilateral (n = 146, 59.8%). Patients with SD-U showed a higher prevalence of female predominance, younger age at diagnosis, bilateral involvement, chronic course, increased erythrocyte sedimentation rate value, and antinuclear antibody positivity compared with patients with idiopathic uveitis (p < 0.05). Uveitis-related complications occurred in 105 (43%) patients, with the most common being posterior synechiae (n = 60, 24.6%). Ocular surgery was required for 7 patients (5.3%) in idiopathic uveitis and for 14 patients (12.4%) in SD-U group.</p><p><strong>Conclusion: </strong>Our study demonstrated that the antinuclear antibody positivity and the high erythrocyte sedimentation rate values were identified as significant, independent predictors for SD-U in patients referred with noninfectious uveitis.</p>","PeriodicalId":14745,"journal":{"name":"JCR: Journal of Clinical Rheumatology","volume":" ","pages":""},"PeriodicalIF":2.4,"publicationDate":"2025-03-12","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"143615255","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":4,"RegionCategory":"医学","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}
{"title":"Complete Ossification of the Acetabular Roof in a Patient With Mild Hip Osteoarthritis.","authors":"Angelo Nigro","doi":"10.1097/RHU.0000000000002223","DOIUrl":"10.1097/RHU.0000000000002223","url":null,"abstract":"","PeriodicalId":14745,"journal":{"name":"JCR: Journal of Clinical Rheumatology","volume":" ","pages":""},"PeriodicalIF":2.4,"publicationDate":"2025-03-06","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"143542222","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":4,"RegionCategory":"医学","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}
Leonard V K Kupa, Ana Cristina Medeiros-Ribeiro, Nádia E Aikawa, Sandra G Pasoto, Eduardo F Borba, Ana Paula L Assad, Carla G S Saad, Emily F N Yuki, Luciana P C Seguro, Danieli Andrade, Samuel K Shinjo, Percival D Sampaio-Barros, Andrea Y Shimabuco, Júlio Cesar B Moraes, Vanderson S Sampaio, Henrique A M Giardini, Clovis A A Silva, Eloisa Bonfá
{"title":"Disease Safety, Immunogenicity, and Efficacy of Recombinant Herpes Zoster Vaccine (RZV or Shingrix) in Autoimmune Rheumatic Diseases: Launching a Randomized Phase 4 Study.","authors":"Leonard V K Kupa, Ana Cristina Medeiros-Ribeiro, Nádia E Aikawa, Sandra G Pasoto, Eduardo F Borba, Ana Paula L Assad, Carla G S Saad, Emily F N Yuki, Luciana P C Seguro, Danieli Andrade, Samuel K Shinjo, Percival D Sampaio-Barros, Andrea Y Shimabuco, Júlio Cesar B Moraes, Vanderson S Sampaio, Henrique A M Giardini, Clovis A A Silva, Eloisa Bonfá","doi":"10.1097/RHU.0000000000002216","DOIUrl":"https://doi.org/10.1097/RHU.0000000000002216","url":null,"abstract":"<p><strong>Background: </strong>Patients with autoimmune rheumatic diseases (ARDs) are at an increased risk for herpes zoster (HZ). Vaccination is recommended for this population.</p><p><strong>Objective: </strong>The aim of this study was to evaluate the safety of vaccination with the recombinant zoster vaccine (Shingrix) in ARD patients, humoral immunogenicity (HI), cellular immunogenicity (CI), and the incidence of HZ.</p><p><strong>Methods: </strong>This randomized, double-blind, placebo-controlled phase 4 study involves 1180 ARD patients and a control group (CG) of 393 balanced healthy individuals, aged ≥50 years. ARD patients will be randomly assigned in a blinded manner (1:1 ratio) to 2 groups: vaccine or placebo (on days 0 and 42), administered intramuscularly. Outcomes will be assessed at baseline, 6 weeks, and 12 weeks after vaccination, including disease activity (using specific disease activity scores), HI, and CI. Adverse events will be assessed using a standardized questionnaire after each vaccine dose. Incident HZ cases will be monitored throughout the study. One year following the second dose, the persistence of HI and CI will be evaluated in both ARD patients and CG. HI and CI will be assessed using serum concentrations of anti-gE antibodies and the frequencies of gE-specific CD4+ T cells, respectively. Comparisons of anti-gE titers between ARD patients and CG at different time points will be analyzed using 2-way repeated-measures analysis of variance. Multiple regression analysis will be conducted, with a positive immune response as the dependent variable, and variables with p < 0.2 from univariate analysis as independent variables.</p><p><strong>Conclusions: </strong>This large trial addresses a critical gap by examining disease safety, efficacy, adverse effects, and immunogenicity, considering the impact of diverse therapies following recombinant zoster vaccine administration in ARD patients.</p>","PeriodicalId":14745,"journal":{"name":"JCR: Journal of Clinical Rheumatology","volume":" ","pages":""},"PeriodicalIF":2.4,"publicationDate":"2025-03-04","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"143556910","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":4,"RegionCategory":"医学","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}
{"title":"Granulomatous Synovitis Caused by a Mycobacterial Avium-Intracellulare Complex.","authors":"Tomomi Tada, Shinji Higa","doi":"10.1097/RHU.0000000000002185","DOIUrl":"10.1097/RHU.0000000000002185","url":null,"abstract":"","PeriodicalId":14745,"journal":{"name":"JCR: Journal of Clinical Rheumatology","volume":" ","pages":"e11"},"PeriodicalIF":2.4,"publicationDate":"2025-03-01","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"142813273","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":4,"RegionCategory":"医学","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}
Jesica Romina Gallo, Cristian Froullet, Alejandro Varizat, Romina Andrea Calvo, Cecilia Pisoni, Micaela Cosatti, Ana Bertoli, Sergio Paira
{"title":"Clinical and Imaging Pulmonary Manifestations in IgG4-Related Disease.","authors":"Jesica Romina Gallo, Cristian Froullet, Alejandro Varizat, Romina Andrea Calvo, Cecilia Pisoni, Micaela Cosatti, Ana Bertoli, Sergio Paira","doi":"10.1097/RHU.0000000000002160","DOIUrl":"10.1097/RHU.0000000000002160","url":null,"abstract":"<p><strong>Objectives: </strong>The aims of this study were to describe the frequency of pleuropulmonary computed tomography (CT) findings in patients with IgG4-related disease (IgG4-RD) and to compare clinical and laboratory characteristics between patients with and without pleuropulmonary involvement in chest CT.</p><p><strong>Methods: </strong>This is a study conducted within the IgG4-RD study group of the Argentine Society of Rheumatology (GESAR IgG4) cohort of patients with IgG4-RD. Member centers of the group were requested to submit pulmonary CT scans of the patients. Lung lesions were classified into 4 subtypes: (1) nodules, (2) ground-glass opacity, (3) interstitial-alveolar involvement, and (4) bronchovascular involvement. The presence of pleural involvement and mediastinal adenopathy was also assessed.</p><p><strong>Results: </strong>We examined data from 28 patients, with 17 (61%) showing pulmonary involvement. The subtypes of pulmonary involvement, in order of frequency, were as follows: type 4 (n = 17, 100%), type 3 (n = 10, 59%), type 2 (n = 6, 36%), and type 1 (n = 5, 29%). Pleural lesions were observed in 2 (12%) cases, and mediastinal adenopathies were found in 4 (23%) cases. No demographic, clinical, or laboratory differences were noted between patients with and without pulmonary involvement, except for serum levels of IgG4, which were higher among patients without pulmonary involvement (339.0 [293.1-1592.1 mg/dL] vs 2869 [1156.3-4037.4 mg/dL]; p = 0.022).</p><p><strong>Conclusions: </strong>In this case series, the predominant subtype of pulmonary involvement was septal thickening and increased bronchovascular tissue. Patients with and without pleuropulmonary involvement exhibited similar clinical and laboratory manifestations, except for serum IgG4, which was higher in patients without pleuropulmonary involvement.</p>","PeriodicalId":14745,"journal":{"name":"JCR: Journal of Clinical Rheumatology","volume":" ","pages":"47-52"},"PeriodicalIF":2.4,"publicationDate":"2025-03-01","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"143005533","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":4,"RegionCategory":"医学","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}
John B Miller, Ting Yang, Alison W Rebman, Laura Cappelli, Clifton O Bingham, Marcia Daniela Villegas de Flores, Erika Darrah, John N Aucott
{"title":"Anti-RA33 Antibodies Are Present in Patients With Lyme Disease.","authors":"John B Miller, Ting Yang, Alison W Rebman, Laura Cappelli, Clifton O Bingham, Marcia Daniela Villegas de Flores, Erika Darrah, John N Aucott","doi":"10.1097/RHU.0000000000002176","DOIUrl":"10.1097/RHU.0000000000002176","url":null,"abstract":"<p><strong>Background/objective: </strong>To determine if anti-RA33 antibodies, which can be seen in early forms of inflammatory arthritis, are present in patients with Lyme arthritis (LA).</p><p><strong>Methods: </strong>Anti-RA33 antibodies were tested using a commercially available assay in patients with LA (n = 47) and compared with patients with erythema migrans who returned to health (EM RTH, n = 20) and those with post-treatment Lyme disease (PTLD) (n = 50), characterized by noninflammatory arthralgia, as an observational comparative study utilizing Lyme-exposed patients from various original cohorts.</p><p><strong>Results: </strong>We found that anti-RA33 was present in higher proportions of patients with LA (23.4% vs. 0%, p = 0.001) and PTLD (12.0% vs. 0%, p = 0.040) than healthy controls. There was also a trend toward a higher percentage of anti-RA33 positivity in patients with EM RTH versus controls (10.0% vs. 0%, p = 0.080). There were no statistically significant differences among groups of patients with LA, PTLD, and EM RTH ( p ≥ 0.567). There was also no difference in the proportion of patients with antibiotic-responsive LA compared with those with persistent synovitis after antibiotics, termed post-infectious LA, and there were no differences in clinical manifestations, musculoskeletal ultrasound evaluation (synovial hypertrophy, power Doppler, tendinopathy), or patient-reported outcomes based on anti-RA33 status.</p><p><strong>Conclusions: </strong>This is the first study to identify anti-RA33 antibodies in patients with LA, though these antibodies did not identify a unique clinical subset of patients in this cohort. Unexpectedly, we found anti-RA33 antibodies at similar levels in patients with PTLD and EM RTH; further study is needed to determine the relevance of this finding.</p>","PeriodicalId":14745,"journal":{"name":"JCR: Journal of Clinical Rheumatology","volume":" ","pages":"65-70"},"PeriodicalIF":2.4,"publicationDate":"2025-03-01","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"https://www.ncbi.nlm.nih.gov/pmc/articles/PMC11902579/pdf/","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"142687050","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":4,"RegionCategory":"医学","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"OA","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}